Marco Terreni et al.
FULL PAPERS
ics, Academic Press, New York, 1982, pp. 371–437;
b) M. F. Rein, F. B. Westervelt, M. A. Sande, Antimicrob.
Agents Chemother. 1973, 4, 366–371; c) M. Nishida, T.
Murakawa, T. Kamimura, N. Okada, H. Sakamoto, S. Fu-
kada, S. Nakamoto, Y. H. Yokota, K. Miki, Antimicrob.
Agents Chemother. 1976, 10, 1–13; d) T. Noto, T. Neha-
shi, H. Endo, M. Saito, S. Matsubara, Y. Harada, S. Suzu-
ki, H. Ogawa, K. Koyama, J. Antibiot. 1976, 29, 1058–
1070.
Multienzymatic Synthesis of Cefonicid (8)
To a solution of cephalosporin C (4.15 g) in 25 mM phosphate
buffer pH 8 (160 mL) at 258C the enzyme derivatives of DAO
(300 UI) and GA (500 UI) were added under magnetic stirring
(200 rpm). During the reaction, a continuous flow of O2 was
maintained and the pH was kept constant by automatic titra-
tion. The reaction was monitored by HPLC (3% acetonitrile,
20 mM ammonium acetate buffer, pH 3.2, flow 1.5 mL/min; l
274 nm). After 3 hours, the complete deacylation of cephalo-
sporin C into 7-ACA (Rt¼3.24 min) was achieved and the re-
action mixture was filtered. The crude solution of 7-ACA was
used for the next reaction by addition of 1 (4.98 g) dissolved
in methanol (40 mL). The mixture was cooled to 48C and the
pH adjusted at 6.5. Immobilized PGA (10 g) was then added
under magnetic stirring (200 rpm) keeping the pH constant
by automatic titration. The reactions were monitored by
HPLC analysis at 274 nm using the analytical conditions re-
ported above for 6. When the maximum yield had been ach-
ieved, the reaction mixture was filtered. The solution of the
crude product 6, obtained after filtration of the immobilized
PGA, was used without purification for 3’-functionalization
to obtain cefonicid (8). In this reaction, SMT (3.92 g) was dis-
solved in the crude solution of 6 obtained after enzymatic acy-
lation. The mixture was heated at 658C at pH 6.5 for 4 hours af-
fording 8 in 50% yield as evaluated by HPLC analysis per-
formed as reported above at 274 nm and using an external
standard of “Cefonicid bisodic salt – USP Working standard”.
From the aqueous solution obtained after the last chemical
step, cefonicid was isolated as its disodium salt prepared with
sodium 2-ethylhexanoate in organic medium following the
procedure reported above but performing the extraction with
a larger volume of THF (6ꢁ80 mL). After concentration of
the THF extracts, the sodium salt was prepared dissolving the
oil obtained in 90 mL of a mixture of acetone/ethanol (2:1)
and dropping this solution into a solution of 2.5 g of sodium
2-ethylhexanoate in 45 mL of acetone/ethanol (2:1) cooled
at 48C. The white precipitate obtained was filtered and dried
under vacuum. Cefonicid bisodium salt was obtained in 35%
yield (2.0 g). The product was analyzed by HPLC as reported
above for the enzymatic synthesis. The purity of the isolated ce-
fonicid (8) as evaluated by HPLC analysis was 92% at 220 nm
and 94% at 254 nm.
[2] a) L. Sogli, D. Terrassan, G. Ribaldone, US Patent
5,387,679, 1995; b) W. Dꢂrckheimer, J. Blumbach, R.
Lattrel, K. H. Scheunemann, Angew. Chem. Int. Ed.
Engl. 1985, 24, 180–202.
[3] T. J. Polansky, US Patent 4,576,937, 1986.
[4] M. Brenner, V. Renganathan, US Patent WO 92/17600,
1992.
´
[5] O. Hernandez-Justiz, M. Terreni, G. Pagani, J. L. Garcꢃa-
´
´
´
Lopez, J. M. Guisan, R. Fernandez-Lafuente, Enzyme
Microb. Technol. 1999, 25, 336–343.
[6] a) J. I. Won, C. G. Kim, J. H. Kim, J. H. Lee, Y. J. Jeon,
Appl. Biochem. Biotechnol. 1998, 69, 1–9; b) M. Kostadi-
nov, A. Nikolov, N. Tsoneva, N. Petkov, Appl. Biochem.
Biotechnol. 1992, 33, 177–182.
[7] S. H. Done, J. A. Branningam, P. C. E. Moody, R. E. Hu-
bard, J. Mol Biol. 1998, 284, 463–475.
[8] R. Fernandez-Lafuente, C. M. Rossel, J. M. Guisan, En-
zyme Microb. Technol. 1998, 22, 583–587.
[9] N. Stambolieva, Z. Mincheva, B. Galunsky, Biocat. and
Biotrans. 1998, 16, 225–232.
´
´
[10] R. Fernandez-Lafuente, C. M. Rosell, J. M. Guisan, En-
zyme Microb. Technol. 1998, 23, 305–310.
´
`
[11] O. Hernandez-Justiz, R. Fernandez-Lafuente, J. M. Gui-
`
san, P. Negri, G. Pagani, M. Pregnolato, M. Terreni, J.
Org. Chem. 1997, 62, 9099–9106.
[12] M. Terreni, G. Pagani, D. Ubiali, R. Fernandez-Lafuente,
C. Mateo, J. M Guisan, Biorg. Med. Chem. Letter 2001,
11, 2429–2432.
[13] a) V. Kasche, Enzyme Microb. Technol. 1986, 8, 4–16;
b) V. Kasche, U. Haufler, L. Riechman, Meth. Enzymol.
1987, 136, 280–292.
[14] a) C. E. McVey,. M. A. Walsh, G. G. Dodson, K. S. Wil-
son, J. A. Brannigan, J. Mol. Biol. 2001, 313, 139–150;
com) was used to depict the structure of the complex.
[15] A. Plaskie, E. Roets, H. Vanderhaeghe, J. Antibiotics
1978, 31, 783–788.
Acknowledgements
We thank Farmabios S.r.l. (Gropello Cairoli, PV, Italy) for fi-
nancial support and Recordati S.p.a. (Opera, MI, Italy) for the
enzymes. We thank Dr. A. Rampino for his help in the early
stages of the project and Dr. D. Ubiali for helpful discussion.
This work has been partially funded by the Spanish CICYT
(projects BIO2001-2259 and PPQ 2002-01231)
´
´
[16] a) J. M. Guisan, R. Fernandez-Lafuente, V. Rodriguez,
A. Bastida, R. M. Blanco, G. Alvaro, in: Stability and Sta-
bilization of Enzymes, Elsevier Science Publishers, The
´
Netherlands, 1993, pp. 55–62; b) G. Alvaro, R. Fernan-
´
dez-Lafuente, R. M. Blanco, J. M. Guisan, Appl. Bio-
chem. Biotechnol. 1990, 26, 181–195; c) J. M. Guisan,
Enzyme Microb. Technol. 1988, 10, 375–382.
[17] a) M. G. Kim, S. B. Lee, J. Mol. Cat. B: Enzym. 1996, 1,
71–80; b) M .G. Kim, S. B. Lee, J. Mol. Cat. B: Enzym.
1996, 1, 181–190; c) M. G. Kim, S. B. Lee, J. Mol. Cat.
B: Enzym. 1996, 1, 201–211.
References and Notes
[1] a) J. A. Webber, W. J. Wheeler, Antimicrobial and phar-
macokinetic properties of newer penicillins and cephalo-
sporins. In: Chemistry and Biology of b-Lactam Antibiot-
128
ꢀ 2005 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
asc.wiley-vch.de
Adv. Synth. Catal. 2005, 347, 121–128